These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38961202)

  • 1. Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Onji H; Tate S; Sakaue T; Fujiwara K; Nakano S; Kawaida M; Onishi N; Matsumoto T; Yamagami W; Sugiyama T; Higashiyama S; Pommier Y; Kobayashi Y; Murai J
    Oncogene; 2024 Jul; ():. PubMed ID: 38961202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
    Onji H; Murai J
    Cancer Sci; 2022 Sep; 113(9):2943-2951. PubMed ID: 35766436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
    Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
    Rathkey D; Khanal M; Murai J; Zhang J; Sengupta M; Jiang Q; Morrow B; Evans CN; Chari R; Fetsch P; Chung HJ; Xi L; Roth M; Filie A; Raffeld M; Thomas A; Pommier Y; Hassan R
    J Thorac Oncol; 2020 May; 15(5):843-859. PubMed ID: 32004714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARPi, BRCA, and gaps: controversies and future research.
    Dibitetto D; Widmer CA; Rottenberg S
    Trends Cancer; 2024 Jul; ():. PubMed ID: 39004561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
    Murai J; Thomas A; Miettinen M; Pommier Y
    Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The
    Simoneau A; Xiong R; Zou L
    Genes Dev; 2021 Sep; 35(17-18):1271-1289. PubMed ID: 34385259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
    Kim JJ; Lee SY; Choi JH; Woo HG; Xhemalce B; Miller KM
    Mol Cell; 2020 Oct; 80(2):327-344.e8. PubMed ID: 32966758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13.
    Fujiwara K; Maekawa M; Iimori Y; Ogawa A; Urano T; Kono N; Takeda H; Higashiyama S; Arita M; Murai J
    iScience; 2023 Dec; 26(12):108529. PubMed ID: 38125019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FANCM promotes PARP inhibitor resistance by minimizing ssDNA gap formation and counteracting resection inhibition.
    Liu Z; Jiang H; Lee SY; Kong N; Chan YW
    Cell Rep; 2024 Jul; 43(7):114464. PubMed ID: 38985669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.
    Akashi H; Yachida N; Ueda H; Yamaguchi M; Yamawaki K; Tamura R; Suda K; Ishiguro T; Adachi S; Nagase Y; Ueda Y; Ueda M; Abiko K; Kagabu M; Baba T; Nakaoka H; Enomoto T; Murai J; Yoshihara K
    Mol Cancer Ther; 2024 Jan; 23(1):106-116. PubMed ID: 37717249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLFN11 Blocks Stressed Replication Forks Independently of ATR.
    Murai J; Tang SW; Leo E; Baechler SA; Redon CE; Zhang H; Al Abo M; Rajapakse VN; Nakamura E; Jenkins LMM; Aladjem MI; Pommier Y
    Mol Cell; 2018 Feb; 69(3):371-384.e6. PubMed ID: 29395061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting replication gaps for cancer therapy.
    Cong K; Cantor SB
    Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication.
    Murai J; Ceribelli M; Fu H; Redon CE; Jo U; Murai Y; Aladjem MI; Thomas CJ; Pommier Y
    Mol Cancer Ther; 2023 Aug; 22(8):985-995. PubMed ID: 37216280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors Display Differential Efficacy in Models of
    Dickson KA; Xie T; Evenhuis C; Ma Y; Marsh DJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replication Gaps Underlie BRCA Deficiency and Therapy Response.
    Panzarino NJ; Krais JJ; Cong K; Peng M; Mosqueda M; Nayak SU; Bond SM; Calvo JA; Doshi MB; Bere M; Ou J; Deng B; Zhu LJ; Johnson N; Cantor SB
    Cancer Res; 2021 Mar; 81(5):1388-1397. PubMed ID: 33184108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-stranded DNA Gap Accumulation is a Functional Biomarker for USP1 Inhibitor Sensitivity.
    da Costa AABA; Somuncu O; Ravindranathan R; Mukkavalli S; Martignetti DB; Nguyen H; Jiao Y; Lamarre BP; Sadatrezaei G; Moreau L; Liu J; Iyer DR; Lazaro JB; Shapiro GI; Parmar K; D'Andrea AD
    Cancer Res; 2024 Jun; ():. PubMed ID: 38885312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.